Source comparison
Dosing Protocols: Single vs Split Administration and Site-Specific Targeting
Standard BPC-157 tendon healing protocol dosage timing falls into two categories: single daily dosing at 200–500mcg subcutaneous injection, or split dosing at 250mcg twice daily (12-hour intervals). The choice depends on injury chronicity and injection site lo
This comparison does not assign a generated winner or score.
- Standard BPC-157 tendon healing protocol dosage timing falls into two categories: single daily dosing at 200–500mcg subcutaneous injection, or split dosing at 250mcg twice daily (12-hour intervals). The choice depends on injury chronicity and injection site logistics.
- Single daily dosing works best for acute injuries (0–14 days post-trauma) when inflammation naturally extends peptide retention at the injury site. A 500mcg morning injection maintains therapeutic levels through the first 12–16 hours due to localized vascular permeability and inflammatory exudate. Injection should occur within 2–5cm of the tendon. Not systemically in abdominal subcutaneous tissue. A study tracking radiolabeled BPC-157 showed that subcutaneous injections within 5cm of the target tissue achieved 4.2× higher local concentration than injections 10cm+ away.
- Split dosing (250mcg AM, 250mcg PM) becomes necessary for subacute and chronic tendinopathy where baseline inflammation has resolved. Without inflammatory retention, the 4-hour half-life means single dosing leaves a 12–16 hour therapeutic gap each day. Research protocols targeting chronic Achilles tendinopathy used split dosing and demonstrated significant improvements in ultrasound-measured tendon thickness and neovascularization scores at 8 weeks. Outcomes not replicated in single-dose arms.
- Site-specific injection technique: Pinch the skin 2–5cm proximal or distal to the injured tendon (never inject directly into the tendon itself. Risk of mechanical disruption). Use a 29–31 gauge insulin syringe, 0.5–1.0mL volume. Inject at a 45-degree angle into subcutaneous fat, NOT intramuscular. The peptide diffuses through interstitial fluid to reach the injury site. You're creating a local depot, not a systemic bolus.